Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma

BACKGROUND: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), is effective for the treatment of advanced non-small cell lung cancer (NSCLC). However, severe adverse events (AEs) have been reported in NSCLC patients treated with bevacizumab. C...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Thorac Dis
Egile Nagusiak: Li, Li-Juan, Chen, Di-Fei, Wu, Guo-Feng, Guan, Wei-Jie, Zhu, Zheng, Liu, Yi-Qian, Gao, Guo-Ying, Qin, Yin-Yin, Zhong, Nan-Shan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AME Publishing Company 2018
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129907/
https://ncbi.nlm.nih.gov/pubmed/30233875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.07.09
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak